Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

<p>Patients with type 2 diabetes at high risk for cardiovascular disease who received empagliflozin had significantly lower rates of the composite cardiac vascular outcome and death from any cause.</p>

Diabetes Drug Reduces Heart Failure, Cardiovascular Death Risk